anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Foscarnet
Trial phase: Phase 3
ATC code: J05AD01
SMILES: O=C(O)P(=O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 88
Group description: intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day

Foscarnet: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
Eligibility criteria:
inclusion criteria: Males and females eligible for the CRRT must have been age 18 years or older and have had AIDS and CMV retinitis. They must have had active CMV despite a minimum of 28 days of previous treatment with an anti-CMV drug. Furthermore, they must have had an absolute neutrophil count greater than or equal to 500 cells/µL, platelet count greater than or equal to 20,000 cells/µL, and a serum creatinine < 2.5 mg/dL in order to tolerate the drug regimens.

exclusion criteria: history of intolerance to ganciclovir or foscarnet, history of therapy involving the combination of foscarnet and ganciclovir, unwillingness to practice appropriate birth control, active drug or alcohol abuse, media opacity, retinal detachment not scheduled for surgical repair
Intervention: Ganciclovir
Trial phase: Phase 3
ATC code: J05AB06 | S01AD09
SMILES: Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 93
Group description: intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day

Ganciclovir: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
Eligibility criteria:
inclusion criteria: Males and females eligible for the CRRT must have been age 18 years or older and have had AIDS and CMV retinitis. They must have had active CMV despite a minimum of 28 days of previous treatment with an anti-CMV drug. Furthermore, they must have had an absolute neutrophil count greater than or equal to 500 cells/µL, platelet count greater than or equal to 20,000 cells/µL, and a serum creatinine < 2.5 mg/dL in order to tolerate the drug regimens.

exclusion criteria: history of intolerance to ganciclovir or foscarnet, history of therapy involving the combination of foscarnet and ganciclovir, unwillingness to practice appropriate birth control, active drug or alcohol abuse, media opacity, retinal detachment not scheduled for surgical repair
Intervention: Cidofovir
Trial phase: Phase 3
ATC code: J05AB12
SMILES: Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 61
Group description: cidofovir intravenous (IV) start off with 5 mg/kg once weekly for two doses then followed by 5 mg/kg every other week

Cidofovir intravenous: intravenous, 5 mg/kg once weekly for two doses, followed by 5 mg/kg every other week
Eligibility criteria:
Inclusion criteria:

Age 13 years or older
Diagnosis of AIDS according to current Centers for Disease Control and Prevention (CDC) definition
Diagnosis of active CMV retinitis by a SOCA-certified ophthalmologist (involvement of any zone or amount of retina is allowed)
Best corrected visual acuity of 20/100 or better in at least one eye
At least one lesion 750 cells/µL or greater
Platelet count 50,000 cells/µL or greater
Willingness and ability, with the assistance of a caregiver if necessary to comply with treatment and follow up procedures
Willingness of all men and women of childbearing potential to practice adequate birth control to prevent pregnancies during the study and for 3 months afterwards
Collection of all baseline data within 5 days prior to randomization
Signed consent statement

Exclusion criteria:

Media opacities that preclude visualization of the fundus of all otherwise eligible eyes
Treatment for CMV retinitis with the ganciclovir intraocular implant within 9 months of study entry
Medical problems or drug or alcohol abuse sufficient to hinder adherence to treatment or follow up procedures
Unwillingness to refrain from breast-feeding during the study and for 3 months afterwards
Intervention: Sertraline
Trial phase: Phase 4
ATC code: N06AB06
SMILES: CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 58
Group description: patients randomized to sertraline 12 week trial does up to 200mgs

Sertraline: 12 week trial dose up to 200mgs
Eligibility criteria:
Inclusion Criteria:

-

Patients must have:

Unipolar major depression (per Diagnostic and Statistical Manuel-IV criteria) with or without melancholia.

Exclusion Criteria:

-

Patients with the following symptoms or conditions are excluded:

Psychotic or atypical subtype of unipolar major depression.
Intervention: Nortriptyline
Trial phase: Phase 4
ATC code: N06AA10
SMILES: CNCCC=C1c2ccccc2CCc2ccccc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 52
Group description: patients randomized to nortriptyline dose adjusted to therapeutic level

Nortriptyline: 12 week trial dose adjusted to therapeutic level
Eligibility criteria:
Inclusion Criteria:

-

Patients must have:

Unipolar major depression (per Diagnostic and Statistical Manuel-IV criteria) with or without melancholia.

Exclusion Criteria:

-

Patients with the following symptoms or conditions are excluded:

Psychotic or atypical subtype of unipolar major depression.
Intervention: Budesonide
Trial phase: Phase 3
ATC code: A07EA06 | D07AC09 | R01AD05 | R03AK07 | R03AK12 | R03AL11 | R03BA02
SMILES: CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 311
Group description: Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn
Eligibility criteria:
Inclusion criteria:

Age 5 to 12 years at time of screening
Chronic asthma as evidenced by one or more of the following historical findings for at least 6 months during the past year:
Asthma symptoms at least 2 times per week
2 or more usages per week of an inhaled bronchodilator
Daily asthma medication
Current asthma symptoms either by diary symptom code of 1 or greater or am or pm PEFR less than 80% of personal best post-bronchodilator value by diary, on 8 or more days during the prn screening period
Methacholine sensitivity: estimated PC20 FEV1 less than or equal to 12.5 mg/ml
Consent of guardian and assent of child
Ability to comply with trial for 5 - 6.5 years

Exclusion criteria:

Presence of one or more of the following confounding or complicating problems:
Any other active pulmonary disease
Any chronic condition presumed to interfere with the successful completion of the project or confound its interpretation
Pulmonary function testing findings suggesting a ventilatory defect other than asthma, or evidence of existing irreversible lung damage
Severe chronic sinusitis or nasal polyposis
Introduction of or a change in allergen immunotherapy within the past month
Use of more than 4 sprays of nasal steroids daily (only beclomethasone allowed)
Pregnancy
Current use of metoclopramide, ranitidine, or cimetidine
Treatment for gastroesophageal reflux
Participation in another drug study
Evidence of severe asthma as indicated by one or more of the following:
Two or more hospitalizations for asthma in the past year
Six or more steroid bursts in the past year
Demonstrated need for continuous use of glucocorticoids, either oral or inhaled
When off inhaled O2-agonist for more than 4 hrs and theophylline for more than 24 hrs, FEV1 less than 65% predicted
Intubation for asthma at any time in the past
Need for 9 or more puffs/day of albuterol for each of 3 consecutive days (excluding preventive use prior to exercise), or nocturnal asthma awakenings more than 1.5 times per week on average, or average diary card symptom code greater than 2, or requirement for other medications to control asthma, during prn screening period
Inability to perform 3 acceptable FVC maneuvers of which at least 2 reproducible FEV1s are within 10% of the largest FEV1
Inability to complete the methacholine challenge or methacholine PC20 FEV1 greater than 12.5 mg/ml
Evidence that patient or family may be unreliable or non-compliant or may move from the metropolitan area before trial completion
Intervention: Nedocromil
Trial phase: Phase 3
ATC code: R01AC07 | R03BC03 | S01GX04
SMILES: CCCc1c2oc(C(=O)O)cc(=O)c2cc2c(=O)cc(C(=O)O)n(CC)c12
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 312
Group description: Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn
Eligibility criteria:
Inclusion criteria:

Age 5 to 12 years at time of screening
Chronic asthma as evidenced by one or more of the following historical findings for at least 6 months during the past year:
Asthma symptoms at least 2 times per week
2 or more usages per week of an inhaled bronchodilator
Daily asthma medication
Current asthma symptoms either by diary symptom code of 1 or greater or am or pm PEFR less than 80% of personal best post-bronchodilator value by diary, on 8 or more days during the prn screening period
Methacholine sensitivity: estimated PC20 FEV1 less than or equal to 12.5 mg/ml
Consent of guardian and assent of child
Ability to comply with trial for 5 - 6.5 years

Exclusion criteria:

Presence of one or more of the following confounding or complicating problems:
Any other active pulmonary disease
Any chronic condition presumed to interfere with the successful completion of the project or confound its interpretation
Pulmonary function testing findings suggesting a ventilatory defect other than asthma, or evidence of existing irreversible lung damage
Severe chronic sinusitis or nasal polyposis
Introduction of or a change in allergen immunotherapy within the past month
Use of more than 4 sprays of nasal steroids daily (only beclomethasone allowed)
Pregnancy
Current use of metoclopramide, ranitidine, or cimetidine
Treatment for gastroesophageal reflux
Participation in another drug study
Evidence of severe asthma as indicated by one or more of the following:
Two or more hospitalizations for asthma in the past year
Six or more steroid bursts in the past year
Demonstrated need for continuous use of glucocorticoids, either oral or inhaled
When off inhaled O2-agonist for more than 4 hrs and theophylline for more than 24 hrs, FEV1 less than 65% predicted
Intubation for asthma at any time in the past
Need for 9 or more puffs/day of albuterol for each of 3 consecutive days (excluding preventive use prior to exercise), or nocturnal asthma awakenings more than 1.5 times per week on average, or average diary card symptom code greater than 2, or requirement for other medications to control asthma, during prn screening period
Inability to perform 3 acceptable FVC maneuvers of which at least 2 reproducible FEV1s are within 10% of the largest FEV1
Inability to complete the methacholine challenge or methacholine PC20 FEV1 greater than 12.5 mg/ml
Evidence that patient or family may be unreliable or non-compliant or may move from the metropolitan area before trial completion
Intervention: ACARBOSE
Trial phase: Phase 3
ATC code: A10BD17 | A10BF01
SMILES: [H]C(=O)[C@H](O)[C@@H](O)[C@]([H])(O[C@@]1([H])O[C@H](CO)[C@@]([H])(O[C@H]2O[C@H](C)[C@@H](N[C@@]3([H])C=C(CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5128
Group description: Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels <6.0%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.
Eligibility criteria:
Inclusion Criteria:

Diagnosed with type 2 diabetes mellitus, as determined by the new American Diabetes Association guidelines, which include a fasting plasma glucose level greater than 126 mg/dl (7.0 mmol/l), or a 2-hour postload value in the oral glucose tolerance test of greater than 200 mg/dl, with confirmation by a retest
For participants aged 40 years or older, history of CVD (heart attack, stroke, history of coronary revascularization, history of peripheral or carotid revascularization, or demonstrated angina)
For participants aged 55 years or older, a history of CVD is not required, but participant must be considered to be at high risk for experiencing a CVD event due to existing CVD, subclinical disease, or 2+ CVD risk factors
HbA1c 7.5%-9% (if on more drugs) or 7.5%-11% (if on fewer drugs)
Intervention: ACARBOSE
Trial phase: Phase 3
ATC code: A10BD17 | A10BF01
SMILES: [H]C(=O)[C@H](O)[C@@H](O)[C@]([H])(O[C@@]1([H])O[C@H](CO)[C@@]([H])(O[C@H]2O[C@H](C)[C@@H](N[C@@]3([H])C=C(CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5123
Group description: Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 to 7.9%. Anti-hyperglycemic agents include multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals.
Eligibility criteria:
Inclusion Criteria:

Diagnosed with type 2 diabetes mellitus, as determined by the new American Diabetes Association guidelines, which include a fasting plasma glucose level greater than 126 mg/dl (7.0 mmol/l), or a 2-hour postload value in the oral glucose tolerance test of greater than 200 mg/dl, with confirmation by a retest
For participants aged 40 years or older, history of CVD (heart attack, stroke, history of coronary revascularization, history of peripheral or carotid revascularization, or demonstrated angina)
For participants aged 55 years or older, a history of CVD is not required, but participant must be considered to be at high risk for experiencing a CVD event due to existing CVD, subclinical disease, or 2+ CVD risk factors
HbA1c 7.5%-9% (if on more drugs) or 7.5%-11% (if on fewer drugs)
Intervention: Sulfamethoxazole
Trial phase: Phase 3
ATC code: G01AE10 | J01EC01 | J01EE01 | J04AM08
SMILES: Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 76
Group description: trimethoprim-sulfamethoxazole: Begin oral Trimethoprim-sulfamethoxazole when they start chemotherapy for multiple myeloma. Assigned treatment consists of TMP-SMX (Septra® or Bactrim®) 1 DS tablet [TMP-SMX DS = 160 mg trimethoprim and 800 mg sulfamethoxazole] every 12 hours for two months..
Eligibility criteria:
Inclusion:

Patient must have a diagnosis of multiple myeloma confirmed by the presence of:

Bone marrow plasmacytosis with >10% abnormal plasma cells or multiple biopsy-proven plasmacytomas, and at least one of the criteria below must be documented:

Myeloma protein in the serum
Myeloma protein in the urine (free monoclonal light chain)
Radiologic evidence of osteolytic lesions (generalized osteoporosis qualifies only if the bone marrow aspirate contains >20% plasma cells)
Patients must have no active infection during the prior seven days and be off all antibiotics for the prior seven days.
Patients cannot have received radiotherapy during the preceding ten days.
Primary therapy for multiple myeloma must start within three days after entry to this study. For purposes of eligibility for this study, myelosuppressive chemotherapy or high-dose dexamethasone based regimens are acceptable as primary therapy. The high-dose dexamethasone regimen must include, at a minimum, dexamethasone 40 mg per day days 1-4, 9-12, 17-20 for the first cycle and 40 mg per day on days 1-4 of the second cycle.
Patients who are to receive dexamethasone alone or dexamethasone with thalidomide are among those eligible for this protocol.
Patients must have a serum creatinine <5.0 mg/dl and not require dialysis at the time of study entry. If patients require dialysis after enrollment, they can continue on the protocol using the adjusted medication guidelines
Written informed consent must be obtained prior to entry.

Exclusion:

- Patients with smoldering myeloma, history of hypersensitivity to fluoroquinolones or trimethoprim, bone marrow transplant or autologous stem cell rescue planned during the first two months of treatment, patients taking theophylline, or patients previously treated with chemotherapy or high-dose dexamethasone
Intervention: Aminolevulinic Acid
Trial phase: Phase 2
ATC code: L01XD04
SMILES: NCC(=O)CCC(=O)O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 180
Group description: 4-6h and 18-24h, 20%, ALA application of superficial and nodular epidermally-derived lesions using ca 633 nm laser irradiation
Eligibility criteria:
DISEASE CHARACTERISTICS:

Diagnosis of 1 of the following:

Actinic keratoses
Histologically proven superficial or nodular basal cell carcinoma (BCC), squamous cell carcinoma in situ (Bowen's disease), or microinvasive squamous cell carcinoma
No nodular BCC greater than 4 mm thick that will not be surgically removed
No carcinoma with uncertain margins requiring Moh's surgery

PATIENT CHARACTERISTICS:

Age:

Not specified

Performance status:

Not specified

Life expectancy:

Not specified

Hematopoietic:

Not specified

Hepatic:

Not specified

Renal:

Not specified

Other:

No known photosensitivity disease
No porphyria or hypersensitivity to porphyrins

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

Not specified

Endocrine therapy:

Not specified

Radiotherapy:

Not specified

Surgery:

Not specified

Other:

No prior treatment with systemic photosensitizer that would cause residual cutaneous photosensitivity during study participation
Intervention: Carboxyamidotriazole
Trial phase: Phase 2
SMILES: NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 55
Group description: CAI with RT

carboxyamidotriazole :

CAI : CAI 250 mg PO plus RT followed by 4wks CAI alone followed by 8wks CAI then MRI if stable or better continue until progression and then follow for survival

radiation therapy :
Eligibility criteria:
Inclusion Criteria:

Patients must have histologically confirmed supratentorial grade IV astrocytoma (glioblastoma multiforme)
Patients must have measurable or non-measurable tumor on the post operative, pretreatment MRI/CT scan (within two weeks of starting treatment)
Patients must not have received prior radiation therapy, chemotherapy, hormonal therapy, immunotherapy or therapy with biologic agents (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy), or hormonal therapy for their brain tumor; glucocorticoid therapy is allowed
Patients must have recovered from the immediate post-operative period and be maintained on a stable steroid regimen (no increase for the last five days)
Absolute neutrophil count >= 1500/mm^3
Platelets >= 100,000/mm^3
Hemoglobin concentration >= 9.0 g/dl
Creatinine =< 1.7mg/dL
Total bilirubin =< 1.2 mg/dl
Transaminases =< 2 times above the upper limits of the institutional normal
Estimated life expectancy greater than 2 months
Patients must give informed consent and understand the investigational nature of this study and its potential risks and benefits
Patients, if female and of childbearing potential must have a negative serum beta-hCG test and must not be breast feeding; all patients with the potential for pregnancy should be counseled and requested to follow acceptable birth control methods to avoid conception
Patients must have a Karnofsky performance status of >= 60%
No other serious concurrent infection or other medical illness should be present which would jeopardize the ability of the patient to receive the drug outlined in this protocol with reasonable safety
Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ; patients with prior malignancies must be disease-free for >= five years

Exclusion Criteria:

Patients must be able to comply with prescribed medical care
Prior therapy for the brain tumor (except surgery)
Prior treatment with antineoplastic agents, including CAI
Intervention: Cyclophosphamide
Trial phase: Phase 3
ATC code: L01AA01
SMILES: O=P1(N(CCCl)CCCl)NCCCO1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 79
Group description: Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.

Cyclophosphamide: Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
Eligibility criteria:
Inclusion Criteria:

Patients with limited or diffuse systemic scleroderma if they had evidence of active alveolitis on examination of bronchoalveolar-lavage (BAL) fluid (defined as neutrophilia of ≥3 percent, eosinophilia of ≥2 percent, or both)on thoracic high-resolution computed tomography (CT), any ground-glass opacity,
Onset of the first symptom of scleroderma other than Raynaud's phenomenon within the previous seven years,
An FVC between 45 and 85 percent of the predicted value
Grade 2 exertional dyspnea according to the baseline instrument of the Mahler Dyspnea Index (as measured with the use of the magnitude-of-task component).

Exclusion Criteria:

A single-breath carbon monoxide diffusing capacity (DlCO) that was less than 30 percent of the predicted value,
A history of smoking within the preceding six months, other clinically significant pulmonary abnormalities,
Clinically significant pulmonary hypertension requiring drug therapy.
Patients taking prednisone at a dose of more than 10 mg per day, those who had previously been treated for more than four weeks with oral cyclophosphamide or had received two or more intravenous doses,
Patients who recently received other potentially disease-modifying medications.
Intervention: Indinavir
Trial phase: Phase 3
ATC code: J05AE02
SMILES: CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2071
Group description: Subcutaneous recombinant interleukin-2 (rIL-2) therapy
Eligibility criteria:
Inclusion Criteria:

HIV positive
Have a CD4 cell count of 300 cells/mm3 or more within 45 days of study entry
Are on combination anti-HIV therapy or are beginning anti-HIV therapy at the time of study entry
Are at least 18 years old

Exclusion Criteria:

Have received IL-2 before
Have cancer requiring chemotherapy
Have evidence of active clinical disease within the past year for any AIDS-defining illness or certain other conditions such as herpes zoster or Chagas disease. (This study has been changed. Previously, patients were ineligible if they had a history of any AIDS-defining illness or certain other conditions.)
Have used certain medications, such as corticosteroids or drugs affecting the immune system, in the 45 days before study entry
Have a nervous system disorder requiring antiseizure medication
Have an autoimmune or inflammatory disease such as inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), psoriasis, optic neuritis, or any autoimmune/inflammatory diseases with potentially life-threatening complications
Are pregnant or breastfeeding